The authors discuss how more efforts need to ensure the methods used to measure the “value” of new therapies include factors that reflect patient heterogeneity.
Amy Miller, PhD
Advertisement
Articles by Amy Miller, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Medicaid MFN Pricing Could Save $8.6 Billion
2
CRC Treatment Delays Linked to Higher Metastasis Risk, Supporting Pathway-Specific Benchmarks
3
Active US Drug Shortages Rise for Third Straight Quarter
4
Early-Onset CKD Mortality Declines Globally as Incidence Continues to Rise
5